Novartis AG NVS announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). The ...

Mekinist (trametinib) is a brand-name drug prescribed for certain types of cancer. It’s available as an oral tablet and oral powder. The cost of Mekinist, with and without insurance, can depend on ...

Mekinist (trametinib) is a prescription drug that’s used to treat certain types of cancers and tumors. Mekinist comes as a powder that a pharmacist mixes into an oral solution and an oral tablet.

Mekinist (trametinib) is a prescription drug that treats specific cancers, including skin, lung, thyroid, and brain. Mekinist’s cost may depend on your dosage, whether you have health insurance, the ...

CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for full approval ...

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application (sNDA) for the use of Tafinlar (dabrafenib) combined with Mekinist (trametinib) as an ...

NEW YORK — The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e., ...

European regulators have expanded the scope of Novartis’ Tafinlar/Mekinist combination to include the treatment of patients with a certain form of lung cancer. European regulators have expanded the ...

The Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K ...

Trametinib 4.7mg; per bottle; pwd for oral soln after reconstitution; strawberry flavored. Store refrigerated at 2°C to 8°C (36°F to 46°F). Store in the original carton to protect from light and ...